NEW YORK (GenomeWeb News) — A Blue Cross and Blue Shield Medical Advisory Panel has decided that Genomic Health’s Oncotype DX assay meets criteria set by the insurance company’s Technology Evaluation Center as a diagnostic for certain breast cancers, Genomic Health said today.
 
At a meeting last month the advisory panel concluded that the test meets its criteria for women with estrogen receptor-positive, node-negative, tamoxifen-treated breast cancer, Genomic Health said.
 

To read the full story....

Register for Free.

...and receive Daily News bulletins.

Already have a GenomeWeb or 360Dx account?
Login Now.

 Senator Lamar Alexander (R-Tenn.), who chairs the Senate health committee, will be retiring at the end of his term, Stat News reports.

UCSF researchers find that having two X chromosomes may contribute to women's longer lifespans, according to Discover's D-brief blog.

The Wall Street Journal reports on the US Centers for Disease Control and Prevention's use of genetic approaches to study foodborne illnesses.

In PNAS this week: immune cell profiling of wild baboons by social status, metabolomics profiling of esophageal tumors, and more.